Branched-chain amino acids supplementation has beneficial effects on the progression of liver cirrhosis: A meta-analysis

Table 2 Patient baseline characteristics of studies included in the meta-analysis, n = 1080

Trail	Group	Albumin in g/dL	Etiology as viral hepatitis/alcoholic/others	Ascites as absent/presence	Hepatic encephalopathy as absent/presence	Esophagogastric varices as absence/presence
Etsushi Kawamura, 2009	BCAA	3.70 ± 0.38	25/2/0	27/0	27/0	27/0
	Control	3.81 ± 0.32	21/2/0	23/0	23/0	23/0
Muto, Y, 2005	BCAA	3.3 ± 0.3	266/20/28	240/74	287/27	144/170
	Control	3.3 ± 0.3	237/32/39	241/66	295/12	121/187
Yutaka Nakaya, 2007	BCAA	3.0 ± 0.4	-	16/3	-	-
	Control	3.0 ± 0.3	-	15/4	-	-
Les, 2011	BCAA	2.9 ± 0.6	24/17/17	-	-	-
	Control	2.9 ± 0.5	18/25/15	-	-	-
Tangkijvanich P, 2000	BCAA	3.81 ± 0.86	6/6/2	-	-	-
	Control	3.66 ± 0.75	7/6/2
Marchesini, G, 1990	BCAA	3.41 ± 0.45	9/20/1	-	-	-
	Control	3.39 ± 0.43	7/16/1	-	-	-
Michel, H, 1985	BCAA	2.61 ± 0.10	4/28/4	10/26	0/36	-
	Control	2.76 ± 0.08	4/29/1	11/23	0/34	-
Ruiz-Margain, A, 2017	BCAA	3.2 ± 0.6	-	-	-	-
	Control	3.2 ± 0.7	-	-	-	-
Masahiro Kobayashi, 2008	BCAA	3.86 ± 0.26	-	19/0	19/0	9/10
	Control	3.90 ± 0.33	-	20/0	20/0	10/10

BCAA: Branched-chain amino acid.